Varicella zoster virus vaccine - Sinovac (Dalian) Vaccine Technology

Drug Profile

Varicella zoster virus vaccine - Sinovac (Dalian) Vaccine Technology

Alternative Names: Live attenuated varicella vaccine - Sinovac Biotech/Dalian Vaccine Technology; Varicella zoster vaccine - Sinovac Biotech/Dalian Vaccine Technology

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Sinovac (Dalian) Vaccine Technology
  • Developer Sinovac (Dalian) Vaccine Technology
  • Class Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Varicella zoster virus infections

Most Recent Events

  • 25 Sep 2017 Preliminary efficacy data from a phase III trial in Varicella zoster virus infections released by Sinovac Biotech
  • 25 Sep 2017 Sinovac Biotech completes clinical trial for Varicella zoster virus infections (In infants, In children, In volunteers, Prevention) before September 2017
  • 24 Sep 2017 Sinovac Biotech initiates clinical trial for Varicella zoster virus infections (In infants, In children, In volunteers, Prevention) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top